<DOC>
	<DOCNO>NCT01953107</DOCNO>
	<brief_summary>The prevalence anemia gynecologic oncology new patient see previous study high 35-59 % . population include woman several type gynecologic malignancy . Therefore , assume origin anemia due anemia chronic disease iron deficiency anemia . No previous study look efficacy oral iron supplementation concurrent Vitamin C woman newly diagnose gynecologic malignancy . Hypothesis : In newly diagnose gynecologic oncology patient surgical candidate treatment 3-6 week oral ferrous fumarate 300 mg day improve mean change hemoglobin level , baseline pre-operative , comparison placebo .</brief_summary>
	<brief_title>Oral Iron v . Placebo Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates .</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Ferrous fumarate</mesh_term>
	<criteria>Over age 18 Scheduled primary operative procedure within 36 week initial consult clinic visit endometrial cancer , uterine sarcoma , cervical cancer , ovarian/fallopian tube cancer patient pelvic mass high suspicion gynecologic malignancy . Patient know allergy ferrous fumarate . Patient 's IV Iron erythropoietin treatment time recruitment Patient 's primary surgical candidate . Patient 's know hemoglobinopathy hypoproliferative hematologic disorder Patient significant active vaginal bleeding Patient hemoglobin &lt; 80 g/L remove randomization refer blood conservation Sunnybrook Health SCiences Centre .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Uterine cancer</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Oral iron</keyword>
</DOC>